

Randomized
(n=226)

Randomized to receive Nicardipine
(n=110)

Received study drug as assigned
(n=109)

Patient withdrew consent and lost to
follow-up (n=1)

Analysed

- included in safety analysis (n=110)
- included in primary endpoint analysis (n=109)

Randomized to receive Labetalol
(n=116)

Received study drug as assigned
(n=116)

Patient withdrew consent and lost to
follow-up (n=2)

Analysed

- included in safety analysis (n=116)
- included in primary endpoint analysis (n=114)